Detect pathogenic EPHB4 variants. Confirm diagnosis in individuals with findings suggestive of capillary malformation-arteriovenous malformation syndrome type 2.
Polymerase Chain Reaction/Sequencing
Within 2 weeks
Lavender (EDTA), Pink (K2EDTA), or Yellow (ACD).
Transport 3 mL whole blood. (Min: 1 mL)
Ambient: 1 week; Refrigerated: 1 month; Frozen: 6 months
Background Information for Capillary Malformation-Arteriovenous Malformation 2 (EPHB4) Sequencing:
Characteristics of Capillary Malformation-Arteriovenous Malformation (CM-AVM): Multifocal, randomly distributed, capillary malformations (CM) that may be associated with a fast-flow lesion (arteriovenous malformations [AVM] or arteriovenous fistula). Fast-flow lesions in the skin, muscle, bone, or central nervous system can cause life-threatening complications such as bleeding, congestive heart failure, or neurological consequences. Capillary malformation-arteriovenous malformation syndrome type 1 (CM-AVM1) is caused by RASA1 pathogenic variants; capillary malformation-arteriovenous malformation syndrome type 2 (CM-AVM2) is caused by EPHB4 pathogenic variants.
Incidence: Estimated at 1 in 20,000 for CM-AVM1 and 1 in 12,000 for CM-AVM2.
Inheritance: Autosomal dominant.
Penetrance: 90-95 percent.
Cause: Pathogenic EPHB4 or RASA1 gene variants.
Gene Tested: EPHB4 only.
Clinical Sensitivity: Not well established, at least 15 percent.
Methodology: Bidirectional sequencing of all coding regions and intron-exon boundaries of the EPHB4 gene.
Analytical Specificity and Sensitivity: 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Regulatory region variants, deep intronic variants, and large deletions/duplications will not be detected. Variants in genes other than EPHB4 are not detected.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|3001130||CMAVM EPHB4 FGS Specimen|
|3001131||CMAVM EPHB4 FGS Interpretation|
- CM-AVM2, Capillary Malformation-Arteriovenous Malformation2